01 February 2023 : Database Analysis
Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
Marcin Warpechowski1CD, Jędrzej Warpechowski2AEF*, Anita Pieńkowska3BEF, Szymon Sagała2BEF, Robert Milewski
4CDE
DOI: 10.12659/MSM.938827
Med Sci Monit 2023; 29:e938827
Table 1 General characteristics of the study group of ulcerative colitis patients treated with Infliximab or Vedolizumab. (Word 2016, Microsoft Office).
| All patients | |
|---|---|
| Number of patients | 35 |
| Gender: male/female | 27/8 |
| Age at diagnosis, median (interquartile range) | 28 (18–36) years |
| Age at start of therapy, median (interquartile range) | |
| Vedolizumab | 23 (18–31) years |
| Infliximab | 32 (21–38) years |
| Disease duration, median (interquartile range) | 7 (4–10) years |
| UC location: proctitis/left-sided/pancolitis | 2/15/18 |
| Contaminant therapies, n% | |
| Immunomodulators | 9 (25.7%) |
| Corticosteroids | 6 (17.14%) |
| Mesalamine | 21 (60%) |
| Sulfasalazine | 2 (5.7%) |
| Partial Mayo score, median (interquartile range) | 7 (6–8) |
| WBC (/μl), median (interquartile range) | 7950 (6025–9380) |
| Platelet (×10/μl), median (interquartile range) | 257 (221–301) |
| Neutrophils (×10/μl), median (interquartile range) | 4.718 (3.217–5.55) |
| Hemoglobin (g/dl), median (interquartile range) | 13.25 (11.7–14.8) |
| CRP (mg/l), median (interquartile range) | 2.75 (1.2–6.4) |
| MPV (fl), median (interquartile range) | 9.9 (9.3–10.8) |
| Neutrophil-to-platelet ratio, median (interquartile range) | 17.98 (14.16–21.40) |
| UC – ulcerative colitis, WBC – white blood cells, CRP – C-reactive protein, MPV – mean platelet volume, μl – microliters, g/dl – grams per deciliter, mg/l – milligrams per liter, fl – femtoliters. | |